Emeryville, CA-August 2, 2004 —Acologix, Inc., a privately held biopharmaceutical company, today announced the addition of a key member to its team. Mr. Aki Watanabe has joined Acologix's Board of Directors. "Mr. Watanabe’s broad experience in mergers and acquisitions, financial management, operations, accounting, auditing, and all other business aspects that build a successful company will help accelerate our growth. Our board now has seven members whose expertise covers broad aspects of a biotechnology company operation that will have this growth occur." said Mr. Yoshi Kumagai, President and CEO of Acologix.

Mr. Watanabe was a partner of KPMG LLP New York office from 1990 to 1994. From 1994 to 2002, he was a managing partner of KPMG Corporate Finance. Furthermore, he is a certified public accountant in both Japan and the State of Colorado. He is also the author of “Mergers and Acquisition Handbook” and “M&A global practice” and an invited professor of Kobe University MBA School teaching M&A.

Aki Watanabe currently serves as a managing partner of GCA Corporation, one of a leading M&A advisory firms.

About Acologix, Inc.

Acologix Inc., based in Emeryville, Calif., is a privately held biopharmaceutical company focused on developing and commercializing novel therapeutics primarily for the treatment of metabolic disorders of kidney and bone that comprise significant unmet medical needs. Founded in 1992, the company’s research is centered on the body’s metabolism of minerals and extracellular matrix molecules that form the biological scaffold for bone and connective tissue. This has led to the identification of unique therapeutic candidates for product development and commercialization. Acologix is seeking strategic development, commercial partnerships and licensees with pharmaceutical and biotechnology companies for several of its programs.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix’s business.

Company Contact

Yoshi Kumagai
President & CEO
Phone: 510.379.1073 ext 10
Fax: 510.379.1074